Comparison of the natural history of ulcerative colitis in African Americans and non-Hispanic Caucasians: A historical cohort study

Moore, Lauren; Gaffney, Kristin; López, Rocío; Shen, Bo

doi:10.1002/ibd.21796

Cited by 22 publications

(14 citation statements)

References 20 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to previous studies, we did not identify a disparity in 5-ASA, steroid, biologic, or immunomodulator therapy for either our CD or UC populations [7, 12, 13, 15]. In addition, our study population did not show differences in positive family history in either CD or UC, contrary to previous investigations [7, 10, 12].…”

Section: Discussioncontrasting

confidence: 99%

“…Differences in UC disease extent and upper gastrointestinal CD involvement have each been shown in a single study, but other studies, including ours, have not redemonstrated these differences [1, 7, 12, 13, 15]. In addition, we identified differences in IBD extraintestinal manifestations in AA patients compared to Ca patients in both our UC and CD populations, which is similar with what has been reported in previous studies [7, 8].…”

Section: Discussionsupporting

confidence: 91%

“…This report and several additional studies have also concluded that AA with CD are less likely to have ileal involvement [7, 8, 10, 11]. While there is less data regarding differences in disease extent by race in patients with ulcerative colitis (UC), Moore et al [12] recently reported increased distal colitis and less pancolitis in AA patients with UC. In contrast, two recent comparably sized studies found no significant differences in disease location by race for either UC or CD [1, 13].…”

Section: Introductionmentioning

confidence: 83%

“…Four retrospective studies have demonstrated no difference in overall rates of surgery by race [10, 12, 13, 16]. However, a nationwide analysis of hospital discharges over a 6-year period concluded that AA with CD were less likely to undergo surgery [17].…”

Section: Introductionmentioning

confidence: 99%

“…During this time, investigations have varied in their reports of utilization of medical therapy by race. AA IBD patients have been found in several analyses to receive less corticosteroids, azathioprine, 5-aminosalicylates (5-ASA), and infliximab [12, 13, 15]. However, these results have not been consistently reproduced in other study populations as two retrospective studies demonstrated no differences in medication utilization by race [7, 14].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical Presentation and Disease Course of Inflammatory Bowel Disease Differs by Race in a Large Tertiary Care Hospital

et al. 2014

View full text Add to dashboard Cite

Background While the incidence of inflammatory bowel disease (IBD) among African-Americans (AAs) is increasing, there is limited understanding of phenotypic differences and outcomes by race. Aim To describe disease characteristics of AA patients compared to Caucasian (Ca) patients in a tertiary care population. Methods We performed a cross-sectional review of the IBD registry at the University of Chicago from January 2008 to January 2013. Data regarding race, phenotype, disease onset, disease duration, medical therapy, and surgical treatment were abstracted from the database, then compared via Pearson’s chi-square analysis, Kruskal–Wallis analysis, and logistic regression with a significance level of p < 0.05. Results A total of 1,235 patients with Crohn’s disease (CD) and 541 patients with ulcerative colitis (UC) included 108 AA CD patients and 28 AA UC patients. AA CD patients had an increased rate of IBD-related arthralgias (36.5 vs. 23.9 %, p < 0.01) and surgery (p < 0.01), less ileal involvement (57.8 vs. 71.0 %, p < 0.01), and no differences for other extraintestinal manifestations or disease locations compared to Ca CD patients. AA UC patients were older at diagnosis, had an increased rate of arthralgias (28.6 vs. 14.6 %, p = 0.047) and ankylosing spondylitis/sacroiliitis (7.1 vs. 1.6 %, p = 0.035), with no differences for disease extent or rate of IBD-related surgeries compared to Ca UC patients. There were no differences in medication usage by race for CD and UC patients. Conclusion We identified significant differences in disease characteristics and extraintestinal manifestations between AA and Ca IBD patients in a large tertiary care population. These results have implications for future genotype-phenotype studies.

show abstract